lampalizumab inn antigenbinding fragment humanized monoclonal antibody binds complement factor developed potential treatment geographic atrophy atrophy retinal cells retinal pigment epithelium choriocapillaris secondary agerelated macular one two phase clinical trials spectri interrupted september due failure meet primary end second phase clinical trial chroma also failed meet primary end two failures called question whether complement inhibition sound strategy geographic immune activation dostarlimab ibalizumab monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikilampalizumab